A drug patent isn’t “worth” what the spreadsheet says—it’s worth what it can survive.
In M&A, everyone talks about patent life, exclusivity windows, and peak sales. But the real value of a drug patent often comes down to a less glamorous line ite…
What a Drug Patent Is Really Worth: How Litigation Costs Reshape Acquisition Value Read Post »
Most NDAs Don’t Fail on Science. They Fail on Strategy.
In pharma, we love to talk about molecules—mechanisms, trial design, endpoints, and the elegance of the data. But anyone who’s shepherded an NDA knows the uncomfortable truth: the submission is …
Two clocks. One drug. And a lot of investors betting on the wrong one.
In pharma, timing isn’t just strategy—it’s destiny. Yet too many teams (and too many market narratives) treat “patent expiry” as the finish line. It isn’t.
A recent DrugPatentWatch …
Advil Dual Action, a pain relief medication combining ibuprofen and aspirin, is designed to provide fast and effective relief… https://www.Drugchatter.com/chat/61409/how-quickly-does-advil-dual-action-work/
DrugChatter: How quickly does advil dual action work? Read Post »
Keytruda, also known as pembrolizumab, is a cancer medication developed by Merck & Co. The US Food and Drug Administration… https://www.Drugchatter.com/chat/26764/what’s-the-exact-date-of-keytruda’s-first-fda-approval/
DrugChatter: What’s the exact date of keytruda’s first fda approval? Read Post »
Keytruda, also known as pembrolizumab, is a cancer medication developed by Merck & Co. The US Food and Drug Administration… https://www.Drugchatter.com/chat/26764/what’s-the-exact-date-of-keytruda’s-first-fda-approval/
DrugChatter: What’s the exact date of keytruda’s first fda approval? Read Post »
Keytruda, also known as pembrolizumab, is a cancer medication developed by Merck & Co. The US Food and Drug Administration… https://www.Drugchatter.com/chat/26764/what’s-the-exact-date-of-keytruda’s-first-fda-approval/
DrugChatter: What’s the exact date of keytruda’s first fda approval? Read Post »
Small molecules vs. biologics: the “same” IP fight—different playbooks for generics and biosimilars
Most IP teams treat drug patents as if the strategy is transferable across modalities. It isn’t.
A small-molecule portfolio and a biologics portfolio ma…
Biopharma vendors don’t lose deals because they’re “too late.” They lose because they’re invisible—until it’s too late.
In EU markets, the tender cycle around loss of exclusivity (LoE) is brutal: once the patent clock runs out, procurement teams move f…
Pharma doesn’t always need a new molecule to make billions. It needs a new story.
For years, the industry’s “innovation” narrative has been anchored to breakthrough compounds—new targets, new mechanisms, new patents. But a quieter, more lucrative playb…
Get new actionable insights and updates from BiotechBlog
